Pharmacokinetic Interaction of the Direct Renin Inhibitor Aliskiren with Furosemide and Extended-Release Isosorbide-5-Mononitrate in Healthy Subjects

direct renin inhibitor: aliskiren in chronic kidney disease

the renin-angiotensin-aldosterone system (raas) plays pivotal roles in the pathogenesis of chronic kidney disease (ckd) progression and its increased complications such as hypertension (ht) and cardiovascular diseases (cvd). previous studies suggested that aliskiren a direct renin inhibitor, blocks raas and may be effective for the management of ckd and its complications. this review focuses on...

Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.

Aliskiren (2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamid hemifumarate) is the first in a new class of orally active, nonpeptide direct renin inhibitors developed for the treatment of hypertension. The absorption, distribution, metabolism, and excretion of [(14)C]aliskiren were investigated in four healthy ...

Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.

Intensive efforts have been spent to discover therapeutic, non-peptide and orally effective hypertensive drugs. One drug that emerged from this effort is aliskiren, a direct human renin inhibitor that blocks the conversion of angiotensinogen to angiotensin I (Ang I). In contrast to other antihypertensive agents, aliskiren decreases plasma renin activity (PRA). In healthy human subjects, doses o...

Simultaneous measurement of plasma isosorbide dinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate by gas-liquid chromatography.

Formulation and In Vitro Characterization of Xanthan Gum-Based Sustained Release Matrix Tables of Isosorbide-5- Mononitrate

In the present investigation an attempt has been made to increase therapeutic efficacy, to reduce frequency of administration and to improve patient compliance by developing a sustained release matrix tablets of isosorbide-5-mononitrate. Sustained release matrix tablets of isosorbide-5-mononitrate were developed by using different drug: polymer ratios, such in F1 (1:0.75), F2 (1:1), F3 (1:1.5),...